Microbial dysbiosis in bronchiectasis

The Lancet Respiratory Medicine

Volumn 2, Issue 12, 2014, Pages 945-947

  Hurst, John R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN ETHYLSUCCINATE; MACROLIDE; PLACEBO; ANTIINFECTIVE AGENT;

BACTERIAL LOAD; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DYSBIOSIS; HAEMOPHILUS INFLUENZAE; HUMAN; LOW DRUG DOSE; MICROBIAL DYSBIOSIS; MICROBIOME; NOTE; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS; FEMALE; MALE;

ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; ERYTHROMYCIN ETHYLSUCCINATE; FEMALE; HUMANS; MALE;

EID: 84919843506     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70223-1     Document Type: Note

References (9)

1. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010, 5:e8578.
2. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013, 309:1260-1267.
3. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
4. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013, 309:1251-1259.
5. Serisier DJ Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013, 1:262-274.
6. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med 2014, published online Oct 14. http://dx.doi.org/10.1016/S2213-2600(14)70213-9.
7. Bray JR, Curtis JT An ordination of upland forest communities of southern Wisconsin. Ecol Monogr 1957, 27:325-349.
8. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698. for the COPD Clinical Research Network.
9. Hanage WP Microbiology: microbiome science needs a healthy dose of scepticism. Nature 2014, 512:247-248.